Litcius/Paper detail

Angiopep-2-Modified Carboxymethyl Chitosan-Based pH/Reduction Dual-Stimuli-Responsive Nanogels for Enhanced Targeting Glioblastoma

Panpan Song, Nannan Song, Li Li, Minghao Wu, Zhongxia Lu, Xia Zhao

2021Biomacromolecules52 citationsDOI

Abstract

Glioblastoma (GBM) is a fatal brain tumor with poor prognosis. Blood–brain barrier (BBB) prevents the effective delivery of chemotherapeutic agents to GBM. Herein, we developed a pH/reduction-sensitive carboxymethyl chitosan nanogel (CMCSN) modified by targeting peptide angiopep-2 (ANG) and loaded with doxorubicin (DOX). The multifunctional nanogel (DOX-ANG-CMCSN) exhibited good pH and reduction sensitivity, ideal stability, and biocompatibility. Its hydrodynamic diameter was 190 nm, drug loading was 12.7%, and the cumulative release rate of 24 h was 82.3% under the simulated tumor microenvironment. More importantly, the modification of ANG significantly enhanced BBB penetration and tumor targeting ability both in vivo and in vitro. DOX-ANG-CMCSN achieved 2–3-fold higher uptake and an enhanced antitumor activity compared with nontargeted DOX-CMCSN. Therefore, the targeted nanogels with the pH/reduction dual-stimuli response may provide a promising platform for GBM-targeted chemotherapy.

Topics & Concepts

NanogelDoxorubicinChemistryIn vivoGlioblastomaBiocompatibilityPharmacologyBlood–brain barrierChitosanDrug deliveryIn vitroTargeted drug deliveryDrug carrierCancer researchChemotherapyBiochemistryMedicineInternal medicineCentral nervous systemBiologyOrganic chemistryBiotechnologyNanoparticle-Based Drug DeliveryRNA Interference and Gene DeliveryNanoplatforms for cancer theranostics
Angiopep-2-Modified Carboxymethyl Chitosan-Based pH/Reduction Dual-Stimuli-Responsive Nanogels for Enhanced Targeting Glioblastoma | Litcius